Rowan Walrath

The drug company is spending up to $3.8 billion on the acquisitions Eli Lilly and Company is spending up to $3.8 billion to buy three vaccine makers, supercharging its push into the immunology space.

The drug company is spending up to $3.8 billion on the acquisitions

Lundbeck scientists will use Cradle's artificial intelligence software for 2 programs

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own

Vaxart is weeks away from a key readout from its COVID-19 vaccine-pill trial San Diego —The vaccine developer Vaxart is aiming to get back on track after a turbulent year.

And yes, China is at the forefront San Diego —Pharmaceutical executives and biotech investors spent their time on the prowl at the BIO

White House aide Heidi Overton has been tapped to lead the agency after a tumultuous period

C&EN explores which cities have the ingredients for chemical innovation For any career, a network is everything. For chemists, that network is highly specialized.

Lilly, T1D Fund back the new firm's $50 million financing Just under a year after netting its first US approval for a cancer-fighting menin

German firm is paying ‘mid-double-digit millions' to acquire small-molecule fertility-drug candidates